Improved Survival for Stage IV Sinonasal Small Cell Neuroendocrine Carcinoma Treated with Chemotherapy and Anti-PD-L1 Therapy

Overview

Journal BMJ Case Rep

Specialty General Medicine

Date 2023 Nov 17

PMID 37977842

Authors

Margaret Selesky

Omar Elghawy

Varinder Kaur

Affiliations

Soon will be listed here.

Abstract

Small cell carcinoma neuroendocrine type (SCCNET) is a rare tumour of the head and neck. Due to its infrequency, a paucity of data exists on optimal treatment, and the current paradigm for advanced SCCNET mirrors that of extensive small cell lung cancer. Increasingly, the treatment for extrapulmonary small cell carcinomas like SCCNET has incorporated immune checkpoint inhibitors (ICIs), although the utility of ICIs is not fully understood. We present a case of stage IVC sinonasal SCCNET in a woman in her 90s, who experienced eyelid swelling and unintentional weight loss. After diagnostic work-up, she was treated with etoposide, carboplatin and atezolizumab with a complete response to therapy. The patient had one episode of inflammatory polyarthropathy which resolved with steroids but otherwise tolerated treatment well and is now living with an overall survival of greater than 27 months. This case highlights the long-term efficacy of combination ICIs and chemotherapy in the treatment of SCCNET.

References

Pointer K, Ko H, Brower J, Witek M, Kimple R, Lloyd R . Small cell carcinoma of the head and neck: An analysis of the National Cancer Database. Oral Oncol. 2017; 69:92-98. PMC: 5553627. DOI: 10.1016/j.oraloncology.2017.04.009. View

Ugwu J, Nwanyanwu C, Shelke A . Dramatic Response of a Metastatic Primary Small-Cell Carcinoma of the Pancreas to a Trial of Immunotherapy with Nivolumab: A Case Report. Case Rep Oncol. 2017; 10(2):720-725. PMC: 5582504. DOI: 10.1159/000479315. View

Bracigliano A, Tatangelo F, Perri F, Di Lorenzo G, Tafuto R, Ottaiano A . Malignant Sinonasal Tumors: Update on Histological and Clinical Management. Curr Oncol. 2021; 28(4):2420-2438. PMC: 8293118. DOI: 10.3390/curroncol28040222. View

Frazier S, Kaplan P, Loy T . The pathology of extrapulmonary small cell carcinoma. Semin Oncol. 2007; 34(1):30-8. DOI: 10.1053/j.seminoncol.2006.11.017. View

Ren W, Wu P, Tian J, Chen D, Li S, Liu B . Anti-PD-1 therapy plus chemotherapy showed superior and durable survival benefit in a patient with small cell esophageal cancer: A case report. Thorac Cancer. 2020; 12(2):264-267. PMC: 7812062. DOI: 10.1111/1759-7714.13735. View

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D . Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019; 394(10212):1929-1939. DOI: 10.1016/S0140-6736(19)32222-6. View

Chapurin N, Totten D, Louis P, Lewis Jr J, Chowdhury N, Turner J . Sinonasal Small Cell Carcinoma-Case Series of a Rare Malignancy. Ear Nose Throat J. 2020; 101(6):392-395. DOI: 10.1177/0145561320964640. View

Acheampong E, Abed A, Morici M, Bowyer S, Amanuel B, Lin W . Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cells. 2020; 9(11). PMC: 7693331. DOI: 10.3390/cells9112393. View

Thompson L . World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ear Nose Throat J. 2006; 85(2):74. View

10.

Su S, Bell D, Hanna E . Esthesioneuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma: differentiation in diagnosis and treatment. Int Arch Otorhinolaryngol. 2015; 18(Suppl 2):S149-56. PMC: 4399581. DOI: 10.1055/s-0034-1390014. View

11.

van der Laan T, Plaat B, van der Laan B, Halmos G . Clinical recommendations on the treatment of neuroendocrine carcinoma of the larynx: A meta-analysis of 436 reported cases. Head Neck. 2014; 37(5):707-15. DOI: 10.1002/hed.23666. View

12.

Liu S, Reck M, Mansfield A, Mok T, Scherpereel A, Reinmuth N . Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021; 39(6):619-630. PMC: 8078320. DOI: 10.1200/JCO.20.01055. View

13.

Walenkamp A, Sonke G, Sleijfer D . Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev. 2008; 35(3):228-36. DOI: 10.1016/j.ctrv.2008.10.007. View

14.

Richardson R, Weiland L . Undifferentiated small cell carcinomas in extrapulmonary sites. Semin Oncol. 1982; 9(4):484-96. View

15.

Brennan S, Gregory D, Stillie A, Herschtal A, Manus M, Ball D . Should extrapulmonary small cell cancer be managed like small cell lung cancer?. Cancer. 2010; 116(4):888-95. DOI: 10.1002/cncr.24858. View

16.

Issa K, Ackall F, Jung S, Li J, Jang D, Rangarajan S . Survival outcomes in sinonasal carcinoma with neuroendocrine differentiation: A NCDB analysis. Am J Otolaryngol. 2021; 42(2):102851. DOI: 10.1016/j.amjoto.2020.102851. View

17.

Zhang Y, Zhang Z . The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020; 17(8):807-821. PMC: 7395159. DOI: 10.1038/s41423-020-0488-6. View

18.

Rivero A, Liang J . Sinonasal small cell neuroendocrine carcinoma: a systematic review of 80 patients. Int Forum Allergy Rhinol. 2016; 6(7):744-51. DOI: 10.1002/alr.21734. View

19.

Husnain M, Park W, Ramos J, Johnson T, Chan J, Dasari A . Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection. J Immunother Cancer. 2018; 6(1):66. PMC: 6036694. DOI: 10.1186/s40425-018-0379-x. View

20.

van der Laan T, Iepsma R, Witjes M, van der Laan B, Plaat B, Halmos G . Meta-analysis of 701 published cases of sinonasal neuroendocrine carcinoma: The importance of differentiation grade in determining treatment strategy. Oral Oncol. 2016; 63:1-9. DOI: 10.1016/j.oraloncology.2016.10.002. View